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Objective
To advance the knowledge on how to amplify the
impact of effective clinical interventions to the popula-
tion level, we tested an approach that took the tradi-
tional model of care delivery, which relied on busy
physician practices to initiate treatment and transformed
it into a patient-driven model, enabled by web technol-
ogy and strategic labor distribution among patient,
physician and pharmacist. Varenicline and bupropion
are effective pharmacotherapies for smoking cessation,
but many clinicians do not proactively discuss these
options with their smoker patients. Using cost-free med-
ication as an incentive, our objective was to demonstrate
the feasibility of enrolling smokers via the internet in a
protocol to engage their family physician in a discussion
of smoking cessation treatment with pharmacotherapy.
Method
Participants visited the study website, provided consent
and completed an on-line assessment. Eligible partici-
pants received a personalized script to take to their physi-
cian, who had the option of prescribing bupropion or
varenicline for 12 weeks. Signed scripts were faxed by the
physician’s office to a central pharmacy that couriered
the medication to the patient. Pharmacist provided one
session of brief telephone counseling.
Results
In 2 months, 893 participants enrolled, of whom 524
(59%) visited 419 different physicians to have the script
signed and faxed (265 varenicline, 259 bupropion). All
medication packages were delivered, with only 1.0%
(n = 5) requiring address clarification or reshipment.
At 6-month follow-up, the 7-day point prevalence of
abstinence was 30.3% for varenicline vs. 24.3% for
bupropion (p >0.1; OR (95%CI): 1.4 (0.8-2.2)).
Conclusion
These quit rates are comparable to those seen in rando-
mized clinical trials. The e-patient movement with the
world-wide-web as its forum has patients acting as dri-
vers of their healthcare. This emerging characteristic of
population behavior provides a new opportunity for
rapid scaling-up of implementation of evidence to the
state-or national-level that is otherwise extended to lim-
ited practice settings. This study was funded by the
Ontario Ministry of Health and Long-Term Care.
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